Results 241 to 248 of about 61,437 (248)

Topoisomerase I inhibitors: topotecan and irenotecan

Cancer Treatment Reviews, 1994
G J, Creemers, B, Lund, J, Verweij
openaire   +2 more sources

Topoisomerase I inhibitors

Drugs & Therapy Perspectives, 1995
openaire   +1 more source

Mutagenic activity of topoisomerase I inhibitors

Clinical cancer research : an official journal of the American Association for Cancer Research
Topoisomerase I-directed agents are now in Phase I and II clinical trials and show great promise as potentially important agents for cancer chemotherapy. Because of their mechanism of action they may also be potential mutagens; however, their mutagenicity and oncogenicity still remain to be elucidated.
, Hashimoto, , Chatterjee, , Berger
openaire   +1 more source

DNA topoisomerase I inhibitors.

Cancer chemotherapy and biological response modifiers, 1998
C H, Takimoto, L V, Kieffer, S G, Arbuck
openaire   +1 more source

[Topoisomerase I inhibitor (irinotecan hydrochloride)].

Nihon rinsho. Japanese journal of clinical medicine, 2005
Shoichi, Inoue, Mohamed Kamel, Hassan, Akio, Kanetoshi   +2 more
openaire   +1 more source

Topoisomerase I inhibitors and other new cytotoxic drugs

European Journal of Cancer, 1995
openaire   +2 more sources

Topoisomerase I inhibitors: topotecan and irinotecan.

Cancer practice, 1996
S F, Jones, H A, Burris
openaire   +1 more source

Interfacial Inhibitors of Human Topoisomerase I

2006
openaire   +1 more source